Literature DB >> 12620751

Measles: not just another viral exanthem.

Trevor Duke1, Charles S Mgone.   

Abstract

Measles is the most frequent cause of vaccine-preventable childhood deaths. Infants younger than the recommended age for vaccination are susceptible to the disease, and in developing countries they have a high risk of complications and mortality. Vaccine coverage in excess of 95% interrupts endemic transmission of measles in many countries, but achievement of such coverage almost always requires coordinated supplementary mass vaccination campaigns. There are substantial health gains if countries improve measles vaccine coverage, irrespective of whether or not high coverage is achieved; these gains include much lower measles complication and case fatality rates, long-term interepidemic duration, and possibly non-specific improvements in survival of children. Investigation into the cost-effectiveness of different strategies for measles control, including mass campaigns, two-dose schedules, and young-infant doses, would help countries to formulate control policies appropriate to their setting. Pneumonia is the most common fatal complication associated with measles, and at least 50% of measles-related pneumonias are due to bacterial superinfection. WHO has developed standard case management programmes for measles, but there are several unresolved clinical issues, including optimum indications for antibiotic treatment, the importance of intravenous immunoglobulin, the role of viral coinfection, and the risk of tuberculosis after measles. The priority in worldwide efforts to control measles is to lend support to poor countries, helping them to increase vaccine coverage and sustain improvements to vaccination infrastructure, and to address technical issues with respect to optimum vaccination schedules. Measles represents a specific challenge, whereby partnerships between high-income and developing nations would reduce child mortality in developing countries; such partnerships are not without incentive for high-income countries, since without them imported measles cannot be prevented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620751     DOI: 10.1016/S0140-6736(03)12661-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Measles in a tertiary institution in bida, niger state, Nigeria: prevalence, immunization status and mortality pattern.

Authors:  Muhammed Adeboye; Omotayo Adesiyun; Abdulrasheed Adegboye; Edith Eze; Usman Abubakar; Grace Ahmed; Abdullahi Usman; Solomon Amos; Bf Rotimi
Journal:  Oman Med J       Date:  2011-03

2.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  8 management of allergy, rashes, and itching.

Authors:  M Langran; C Laird
Journal:  Emerg Med J       Date:  2004-11       Impact factor: 2.740

4.  Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization.

Authors:  Rik L de Swart; Selma Yüksel; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 5.  Measles in the United Kingdom: can we eradicate it by 2010?

Authors:  Perviz Asaria; Eithne MacMahon
Journal:  BMJ       Date:  2006-10-28

6.  Ethnicity as a correlate of the uptake of the first dose of mumps, measles and rubella vaccine.

Authors:  Ruth E Mixer; Konrad Jamrozik; David Newsom
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

7.  Measles mimicking HIV seroconversion syndrome: a case report.

Authors:  Mahua T Chatterjee; Margaret Coleman; Gary Brook; Daniel McCrea
Journal:  J Med Case Rep       Date:  2010-02-06

Review 8.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Measles epidemic from 1951 to 2012 and vaccine effectiveness in Guangzhou, southern China.

Authors:  Zhicong Yang; Jianxiong Xu; Ming Wang; Biao Di; Huifeng Tan; Qing He; Yanshan Cai; Jianhua Liang; Wensui Hu; Zhiqiang Dong; Yunqing Yang; Chuanxi Fu
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

10.  Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; David C Muddiman; Robert A Vierkant; Gregory A Poland
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.